Shareholders meeting

MANUFACTURER OF a‘(ey BULK DRUGS & ' IMPORTERS OF DRUGS & PHARMACEUTICALS LTD. SOLVENTS & CHEMICALS H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ® : (022) 23455543 Email: corporate@aareydrugs.com REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE © (02525) 271049 Email: info@aareydrugs.com CIN:L99999MH1990PLC056538 Date : 8" September, 2026 BSE Limited National Stock Exchange of India Limited The Manager, Exchange Plaza Corporate Service Department Bandra Kurla Complex, P.). Towers, Dalal Street, Bandra (E), Mumbai- 400 001 Mumbai - 400051 Scrip Code: 524412 NSE Symbol: AAREYDRUGS Sub: Notice and Integrated Annual Report for 36" Annual General Meeting of Company as required under Regulation 34(1) Ref: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulation 2015 Dear Sir/Ma’am, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Notice of the 36" Annual General Meeting of the Company scheduled to be held on Wednesday, 30th September, 2026 at 03:00 P.M. through Video Conferencing (VC) / Other Audio-Visual Means (OAVM), along with the Integrated Annual Report of the Company for the financial year 2025-26. The Notice and the Annual Report are being circulated to the shareholders through electronic mode today, in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The Notice along with the Annual Report for the financial year 2025-26 is also available on the website of the Company www.aareydrugs.com Brief details of 36th AGM Date and Time of AGM 30th September, 2026 at 03:00 PM Cut off date for evoting 23rd September, 2026 Evoting start date and time 27th September, 2026 at 09.00 AM Evoting end date and time 29th September, 2026 at 05.00 PM Kindly take the above on record and acknowledge the receipt of the same. Thanking You, For Aarey Drugs & Pharmaceuticals Limited Nohat(.s Nimit Ghatalia Director DIN: 07069841 Encl.:a/a ANNUAL REPORT 2025-26 ANNUAL REPORT 2025-26 BOARD OF DIRECTORS Mihir Rajesh Ghatalia Chairman & Managing Director Nimit Rajesh Ghatalia Executive Director Chetan Kiritbhai Mehta Independent Director Lalit Radhakrishna Tulsiani Independent Director Anil Mandal Independent Director Bina Rajesh Ghatalia Woman Director KEY MANAGERIAL PERSONNEL Mira Mihir Ghatalia Chief Financial Officer Kailash Chand Jethlia Company Secretary & Compliance Officer REGISTERED OFFICE E-34, M.I.D.C., Tarapur, Boisar, Dist.Thane. Pincode – 401506 HEAD OFFICE 107, Sahakar Bhavan, 340/348, Narshi Natha Street, Narshi Natha Street, Masjid, Mumbai - 400 WORKS E-34, M.I.D.C Tarapur, Boisar, Dist. Palghar. Pincode – 401506 BANKER State Bank of India, Sakinaka Branch, Andheri (East), Mumbai AUDITORS Motilal & Associates LLP. 304, Orchid Plaza, S.V. Road, Borivali West Mumbai – 400092 ANNUAL REPORT 2025-26 INDEX Particulars Page No. Notice 1-16 Director Report 17-38 Management Discussion and Analysis Report 39-41 Corporate Governance 42-60 CFO Certification 61 Certificates of Non Disqualification of Directors 62-63 Declaration from Independent Directors on Annual Basis 64 Independent Auditors Report 65-92 Balance Sheet 93 Profit and Loss Statement 94 Cash Flow Statement 95 Notes forming Accounts 96-114 ANNUAL REPORT 2025-26 NOTICE NOTICE IS HEREBY GIVEN THAT THE 36TH (THIRTY SIXTH) ANNUAL GENERAL MEETING OF THE MEMBERS OF AAREY DRUGS & PHARMACEUTICALS LIMITED WILL BE HELD ON WEDNESDAY 30TH SEPTEMBER, 2026 AT 3:00 P.M. THROUGH VIDEO CONFERENCING (‘VC’)/OTHER AUDIO VISUAL MEANS (‘OVAM’) TO TRANSACT THE FOLLOWING BUSINESS: The proceedings of the AGM shall be deemed to be conducted at the registered office of the Company which shall be deemed venue of AGM. ORDINARY BUSINESS: 1. TO RECEIVE, CONSIDER AND ADOPT THE AUDITED FINANCIAL STATEMENT OF THE COMPANY FOR THE YEAR ENDED 31ST MARCH, 2026, THE BALANCE SHEET AS ON THAT DATE AND THE REPORTS OF DIRECTORS AND AUDITORS THEREON. To consider and, if thought fit, to pass, with or without modification(s), the following Resolution as an Ordinary Resolution: “RESOLVED THAT the Audited Financial Statement of the Company for the financial year ended March 31, 2026 and the reports of the Board of Directors and Auditors thereon, as circulated to the Members, be and are hereby considered and adopted.” 2. TO APPOINT A DIRECTOR IN PLACE OF MRS. BINA GHATALIA (DIN:01471745), WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HERSELF FOR RE-APPOINTMENT. To consider and, if thought fit, to pass, with or without modification(s), the following Resolution as an Ordinary Resolution: “RESOLVED THAT in accordance with the provisions of Section 152 and other applicable provisions of the Companies Act, 2013, Mrs. Bina Ghatalia (DIN:01471745), who retires by rotation at this meeting, be and is hereby appointed as a Director of the Company.” SPECIAL BUSINESS: 3. APPROVAL OF RELATED PARTY TRANSACTIONS To consider and, if thought fit, to pass, with or without modification(s), the following Resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 188 and other applicable provisions, if any, of the Companies Act, 2013 (“Act”), read with the Companies (Meetings of Board and its Powers) Rules, 2014, Regulation 23(4) and other applicable provisions of the Securities and Exchange Board of India (Listing ANNUAL REPORT 2025-26 Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), as amended from time to time, and subject to such other approvals, consents, permissions and sanctions as may be necessary, consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company (“Board”), including any Committee thereof, to enter into and/or continue with contracts, arrangements and/or transactions with the Related Parties of the Company, as set out below, on such terms and conditions as may be mutually agreed, provided that the aggregate value of transactions with each such Related Party shall not exceed the respective limits specified below during the financial year, notwithstanding that such transactions may be entered into in one or more tranches and are in the ordinary course of business and/or on such terms as may be considered appropriate by the Board: Maximum Value Sr. Name of Related Relationship per Financial Nature of Transactions No. Party Year Office rent; 1 Bina R Ghatalia Director Rs.15 Crores loans/advances and repayment. Company in which Loans/advances, Enam Organics 2 Directors are Rs.45 Crores repayment thereof and India Ltd. substantially interested interest income Loans/advances and 3 Mira M Ghatalia CFO Rs.15 Crores repayment. Loans/advances and 4 Nimit R Ghatalia Director Rs.15 Crores repayment. Loans/advances and 5 Rajesh Ghatalia Relative of Director Rs.15 Crores repayment. Suraj TradelinksPvt. Company in which Loans/advances and 6 Rs.15 Crores Ltd. Director is interested repayment. Nimit Impex Pvt. Company in which Loans/advances and 7 Rs.15 Crores Ltd. Director is interested repayment. Loans/advances, Worth Investment & Company in which 8 Rs.30 Crores repayment thereof and Trading Co. Ltd. Director is interested interest income Aarey Pharma Park Company in which Loans/advances taken and 9 Rs.15 Crores Pvt. Ltd. Director is interested repayment. Loans/advances and 10 Mihir Ghatalia Managing Director Rs.15 Crores repayment. Loans/advances and 11 Ekta Ghatalia Relative of Director Rs.15 Crores repayment. ANNUAL REPORT 2025-26 RESOLVED FURTHER THAT any of the Directors or Company Secretary or Chief Financial Officer of the Company be and is hereby authorised either severally or jointly to do all such acts, deeds and things as may be deemed proper and expedient to give effect to this Resolution.” By order of the Board of Directors For AAREY DRUGS AND PHARMACEUTICALS LIM [Showing first 8,000 characters — download PDF for full document]